Knobbe, Martens, Olson & Bear LLP
Crystalline monomesylate salt of 6-(6-aminopyrazin-2-yl)-n-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine
The present disclosure relates to compounds that are Syk inhibitors or pharmaceutically acceptable salts or co-crystals thereof, and pharmaceutical compositions thereof, and to their use in the treatment of various disease states, including cancer and inflammatory conditions. In particular embodiments, a Syk inhibitor is a crystalline monomesylate salt of 6-(6-aminopyrazin-2-yl)-N-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo-[1,2-a]pyrazin-8-amine of formula 2:
KRONOS BIO, INC.
A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A C A A A A A A A A A A A A A A
A61P A61P A61P A61P A61P A61P A61P A61P A61K A61P A61P A61P A61P A61P A61P A61P A61P A61P A61P A61P A61P A61P A61P A61P A61P A61P A61P A61P A61P A61P A61P A61P C07D A61P A61P A61P A61P A61P A61P A61P A61P A61P A61P A61K A61K A61P A61P
inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional
Jeffrey E. Scott A. Seung H. Jin-Ming Jennifer R. Kevin S. Zhongdong Aaron C. Sundaramoorthi Jianjun Peter A.
Kropf Mitchell Lee Xiong Lo Currie Zhao Schmitt Swaminathan Xu Blomgren